SAN DIEGO, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus" or the "Company") (Nasdaq:APRI) (www.apricusbio.com), announced today that Apricus signed an exclusive license ...
(www.apricusbio.com), today provided a corporate update. "Since the beginning of this year, we have continued to focus our efforts on creating long-term value through our lead product Vitaros® and our ...
Apricus Biosciences has received European approval to market alprostadil 0.3% topical cream (Vitaros) for the treatment of erectile dysfunction (ED), the company announced today. Vitaros is a ...
(Reuters) - Apricus Biosciences Inc said on Monday it was considering options for the company and looking to sell the U.S. rights to its erectile dysfunction cream Vitaros, after the Food and Drug ...
Ferring Pharmaceuticals purchased ex-U.S. assets and rights to Apricus Biosciences’ on-demand topical erectile dysfunction therapy cream Vitaros ® (alprostadil) for potentially $12.7 million. Ferring ...
When looking for treatment for her eye condition, a woman was incorrectly given an erectile dysfunction cream to be used on her eyes, resulting in chemical injury. The woman was prescribed and ...
In 2 randomised controlled trials (RCTs) alprostadil 300 microgram cream statistically significantly improved erectile function and intercourse ability compared with placebo but the average absolute ...
Apricus Biosciences, Inc. ( APRI) announced the launch of its sole approved product, Vitaros in Germany. Vitaros is an on-demand topical cream formulation for treating patients suffering from erectile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback